UBS AM
CAI

UBS AM’s Caris Life Sciences CAI Stock Holding History

UBS AM’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7K Sell
770
-1,148,363
-100% -$20.6M ﹤0.01% 3207
2026
Q1 		$20.5M Sell
1,149,133
-321,162
-22% -$7.02M ﹤0.01% 874
2025
Q4 		$39.7M Buy
1,470,295
+354,104
+32% +$9.97M 0.01% 664
2025
Q3 		$33.8M Buy
1,116,191
+316,078
+40% +$10.1M 0.01% 676
2025
Q2 		$21.4M Buy
+800,113
New +$21.6M ﹤0.01% 1027

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS AM's CAI Position: Q2 2026 in Review

UBS AM reduced its Caris Life Sciences (CAI) stake by 100% in Q2 2026, selling an estimated $20.6M and leaving 770 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3207.

UBS AM first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $39.7M in Q4 2025. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • UBS AM held 770 shares of Caris Life Sciences worth $13.7K as of Q2 2026.
  • UBS AM sold 1,148,363 Caris Life Sciences shares in Q2 2026, an estimated $20.6M.
  • Caris Life Sciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3207 holding.
  • UBS AM first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • UBS AM's Caris Life Sciences position peaked at $39.7M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.